CytoMed Therapeutics Limited (GDTC)
GDTC Stock Price Chart
Explore CytoMed Therapeutics Limited interactive price chart. Choose custom timeframes to analyze GDTC price movements and trends.
GDTC Company Profile
Discover essential business fundamentals and corporate details for CytoMed Therapeutics Limited (GDTC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Apr 2023
Employees
43.00
Website
https://w2.cytomed.sgCEO
Chee Kong Choo
Description
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
GDTC Financial Timeline
Browse a chronological timeline of CytoMed Therapeutics Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Nov 2026
Upcoming earnings on 13 Nov 2026
Earnings released on 30 Jun 2026
Earnings released on 4 May 2026
Earnings released on 27 Apr 2026
Earnings released on 31 Mar 2026
Earnings released on 30 Sept 2025
EPS came in at -$0.07 , while revenue for the quarter reached $105.71k .
Earnings released on 31 Mar 2025
EPS came in at -$0.05 , while revenue for the quarter reached $74.29k .
Earnings released on 30 Sept 2024
EPS came in at -$0.04 , while revenue for the quarter reached $83.26k .
Earnings released on 30 Jun 2024
EPS came in at -$0.05 , while revenue for the quarter reached $61.01k .
Earnings released on 6 May 2024
EPS came in at -$0.05 , while revenue for the quarter reached $63.95k .
Earnings released on 31 Mar 2024
EPS came in at -$0.03 , while revenue for the quarter reached $61.42k .
Earnings released on 30 Sept 2023
EPS came in at -$0.05 , while revenue for the quarter reached $59.70k .
Earnings released on 30 Jun 2023
EPS came in at -$0.10 , while revenue for the quarter reached $77.64k .
Earnings released on 1 May 2023
EPS came in at -$0.10 , while revenue for the quarter reached $80.24k .
Earnings released on 31 Mar 2023
EPS came in at -$0.06 , while revenue for the quarter reached $80.34k .
Earnings released on 30 Sept 2022
EPS came in at -$0.06 , while revenue for the quarter reached $70.23k .
Earnings released on 30 Jun 2022
EPS came in at -$0.07 .
Earnings released on 31 Mar 2022
EPS came in at -$0.04 , while revenue for the quarter reached $20.28k .
Earnings released on 31 Dec 2021
EPS came in at -$0.08 .
Earnings released on 30 Sept 2021
EPS came in at -$0.04 , while revenue for the quarter reached $23.09k .
GDTC Stock Performance
Access detailed GDTC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
